Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/PRKCI_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PRKCI_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PRKCI_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PRKCI_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PRKCI_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PRKCI_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PRKCI_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PRKCI_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000721913 | Oral cavity | LP | Notch signaling pathway | 57/4623 | 172/18723 | 7.60e-03 | 4.18e-02 | 57 |
GO:000701518 | Prostate | BPH | actin filament organization | 147/3107 | 442/18723 | 3.36e-18 | 1.15e-15 | 147 |
GO:190382918 | Prostate | BPH | positive regulation of cellular protein localization | 98/3107 | 276/18723 | 1.46e-14 | 1.84e-12 | 98 |
GO:004819310 | Prostate | BPH | Golgi vesicle transport | 102/3107 | 296/18723 | 3.90e-14 | 4.56e-12 | 102 |
GO:000660518 | Prostate | BPH | protein targeting | 102/3107 | 314/18723 | 2.51e-12 | 2.05e-10 | 102 |
GO:000716316 | Prostate | BPH | establishment or maintenance of cell polarity | 75/3107 | 218/18723 | 9.93e-11 | 5.97e-09 | 75 |
GO:007265916 | Prostate | BPH | protein localization to plasma membrane | 89/3107 | 284/18723 | 5.00e-10 | 2.56e-08 | 89 |
GO:190165310 | Prostate | BPH | cellular response to peptide | 104/3107 | 359/18723 | 2.51e-09 | 1.00e-07 | 104 |
GO:000690017 | Prostate | BPH | vesicle budding from membrane | 30/3107 | 61/18723 | 3.85e-09 | 1.44e-07 | 30 |
GO:199077810 | Prostate | BPH | protein localization to cell periphery | 95/3107 | 333/18723 | 2.78e-08 | 8.13e-07 | 95 |
GO:00109759 | Prostate | BPH | regulation of neuron projection development | 118/3107 | 445/18723 | 5.85e-08 | 1.57e-06 | 118 |
GO:00107208 | Prostate | BPH | positive regulation of cell development | 86/3107 | 298/18723 | 7.11e-08 | 1.85e-06 | 86 |
GO:00313469 | Prostate | BPH | positive regulation of cell projection organization | 98/3107 | 353/18723 | 7.34e-08 | 1.88e-06 | 98 |
GO:009015016 | Prostate | BPH | establishment of protein localization to membrane | 77/3107 | 260/18723 | 1.06e-07 | 2.56e-06 | 77 |
GO:007099718 | Prostate | BPH | neuron death | 98/3107 | 361/18723 | 2.35e-07 | 5.12e-06 | 98 |
GO:004343417 | Prostate | BPH | response to peptide hormone | 109/3107 | 414/18723 | 2.73e-07 | 5.91e-06 | 109 |
GO:00713759 | Prostate | BPH | cellular response to peptide hormone stimulus | 82/3107 | 290/18723 | 3.65e-07 | 7.65e-06 | 82 |
GO:003001010 | Prostate | BPH | establishment of cell polarity | 48/3107 | 143/18723 | 5.10e-07 | 1.03e-05 | 48 |
GO:190307610 | Prostate | BPH | regulation of protein localization to plasma membrane | 38/3107 | 104/18723 | 7.15e-07 | 1.37e-05 | 38 |
GO:190547510 | Prostate | BPH | regulation of protein localization to membrane | 55/3107 | 175/18723 | 8.75e-07 | 1.61e-05 | 55 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PRKCI | SNV | Missense_Mutation | | c.1540N>C | p.Ala514Pro | p.A514P | P41743 | protein_coding | tolerated(0.21) | benign(0.437) | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD |
PRKCI | SNV | Missense_Mutation | | c.1745N>G | p.Phe582Cys | p.F582C | P41743 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
PRKCI | deletion | Frame_Shift_Del | novel | c.1551delN | p.Gly518AspfsTer12 | p.G518Dfs*12 | P41743 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
PRKCI | SNV | Missense_Mutation | novel | c.238G>A | p.Val80Ile | p.V80I | P41743 | protein_coding | tolerated(1) | benign(0.024) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PRKCI | SNV | Missense_Mutation | novel | c.697G>C | p.Glu233Gln | p.E233Q | P41743 | protein_coding | tolerated(0.1) | benign(0.003) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
PRKCI | SNV | Missense_Mutation | | c.862N>C | p.Glu288Gln | p.E288Q | P41743 | protein_coding | tolerated(0.06) | possibly_damaging(0.837) | TCGA-EK-A2RC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PRKCI | SNV | Missense_Mutation | | c.318N>G | p.Phe106Leu | p.F106L | P41743 | protein_coding | tolerated(0.09) | probably_damaging(0.999) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PRKCI | SNV | Missense_Mutation | | c.157N>C | p.Glu53Gln | p.E53Q | P41743 | protein_coding | tolerated(0.11) | possibly_damaging(0.751) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PRKCI | SNV | Missense_Mutation | | c.1376N>T | p.Ser459Phe | p.S459F | P41743 | protein_coding | tolerated(0.06) | possibly_damaging(0.878) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PRKCI | SNV | Missense_Mutation | | c.880G>A | p.Glu294Lys | p.E294K | P41743 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-MY-A5BD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5584 | PRKCI | KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | GSK-269962A | GSK-269962A | |
5584 | PRKCI | KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | ILORASERTIB | ILORASERTIB | |
5584 | PRKCI | KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL608533 | MIDOSTAURIN | |
5584 | PRKCI | KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | SOPHORETIN | QUERCETIN | |
5584 | PRKCI | KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL3545332 | CEP-2563 | |
5584 | PRKCI | KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 135652717 | STAUROSPORINE | |
5584 | PRKCI | KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL574737 | UCN-01 | |
5584 | PRKCI | KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | SOTRASTAURIN | SOTRASTAURIN | |
5584 | PRKCI | KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL565612 | SOTRASTAURIN | |
5584 | PRKCI | KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | INGENOL MEBUTATE | | |